Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$166.08
▼ $0.06 (-0.0%)
Market data updated: 09/19 06:00 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
Not available
Day Range
$165.54 - $167.83
52-Week Range
$145.80 - $212.71
Beta
—
Next Earnings
30.10.2026
Support
$153.41
Resistance
$175.88
AZN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+7.7% (1Y)
Strengths: 15/31 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Golden Cross
SMA 50 recently crossed above SMA 200
Technical
Biggest negative driver
Liquidity risk
Current ratio: 0.94
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
66
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
71
Quality
58
Value
50
Momentum
67
Risk
34
Sentiment
100
Fundamental
68
Institutional
60
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of AstraZeneca PLC has primarily focused on the positive Phase 3 trial results of its **IMFINZI® (durvalumab) combined with tarlatamab**, showing significant improvements in overall and progression-free survival for first-line extensive-stage small cell lung cancer. Additionally, the company’s **Tozorakimab** demonstrated a statistically meaningful reduction in COPD exacerbations in Phase 3 trials (OBERON and TITANIA). No other substantial company-specific developments were highlighted in the provided sources.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about AstraZeneca PLC. News trend score: 100. Reason: 10 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
22
🎯 Conviction (vs. Emotion)
52
Psychology
25
Fundamentals
68
Technical
67
Valuation
50
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-5%
Market Narrative
60
Fundamental Reality
52
Narrative Gap
+8
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant **Loss Aversion** (43) reflects a market reluctant to accelerate downside after a 12.5% drop, despite muted volume and neutral RSI. **Herding** (29) suggests passive alignment with peer declines, while **FOMO** (10) remains dormant due to weak momentum. The **narrative gap** (-3) hints at a slight disconnect between sentiment (49) and technical reality (52), but no extreme bias is active. The key question: *Will traders exit to lock losses, or hold for a rebound?*
Updated: 09/08/2026, 03:54 PM
What could change this?
👥 What the crowd believes
"IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant improvement in overall survival and progression-free survival in first-line extensive-stage small cell lung cancer (Article 3)"
"Tozorakimab demonstrated statistically significant reduction in COPD exacerbations in OBERON and TITANIA Phase III trials (Article 8)"
"Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval (Article 11)"
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 91/100
🔴 Weakest match
Benjamin Graham (Enterprising Investor) — 4/100
🗣️ Why do they disagree?
The methodologies for AZN split sharply between bullish growth-oriented strategies and cautious or bearish frameworks. Peter Lynch’s high score (92) and his 'growth candidate' verdict reflect his focus on underappreciated companies with upside potential, while Edgar Lawrence Smith (80) and Morgan Housel (73) also see it as a long-term hold—aligning with their patient, value-compounding philosophies. However, more conservative voices like Benjamin Graham (23) and Walter Bagehot (25) dismiss it outright, with Graham’s Enterprising Investor variant (4) calling it statistically overpriced, highlighting a stark contrast between fundamental value and growth-driven approaches. Meanwhile, market efficiency skeptics like Jack Schwager (33) and Jesse Livermore (28) reject it entirely, favoring trend-following or contrarian logic, while Howard Marks (64) hedges, warning of potentially inflated expectations.
Peter Lynch
One Up on Wall Street (1989)
🟢 91
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 83
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 80
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 73
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 73
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 68
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 61
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 47
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 42
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 35
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 29
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 25
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 23
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 21
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 19
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 4
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (7 bullish · 4 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
81.6%
Operating Margin
23.4%
Net Margin
17.4%
EBITDA Margin
—
ROE
21.0%
ROA
9.0%
ROIC
—
EPS
$6.60
Cash
$5.71B
Total Debt
$27.82B
Current Ratio
0.94
Debt/Equity
0.61
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 19.2.2026 | $2.153 |
| 18.2.2026 | $2.153 |
| 8.8.2025 | $1.030 |
| 7.8.2025 | $1.030 |
| 21.2.2025 | $2.100 |
| 20.2.2025 | $2.100 |
| 9.8.2024 | $1.000 |
| 8.8.2024 | $1.000 |
| 22.2.2024 | $1.970 |
| 21.2.2024 | $1.970 |
| 10.8.2023 | $0.930 |
| 9.8.2023 | $0.930 |
How is Fair Value calculated? →
Current Price
$166.08
Estimated Fair Value (DCF)
$178.03
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+7.2%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $14.71B | $13.49B |
| 2 | 19.4% | $17.56B | $14.78B |
| 3 | 13.8% | $19.97B | $15.42B |
| 4 | 8.1% | $21.59B | $15.30B |
| 5 | 2.5% | $22.13B | $14.38B |
Base FCF (last actual year)
$11.77B
Terminal Value
$349.00B
Present Value of Terminal Value
$226.83B
Enterprise Value
$300.20B
Net Debt
$22.11B
Equity Value
$278.09B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$31.38
Tangible Book Value per Share (Tangible NAV)
$6.98
Sentiment based on basic keywords (not AI) — 10 positive, 9 neutral, 1 negative out of the last 20 articles.
Yahoo · 18.9.2026
Zacks · 18.9.2026
MT Newswires · 18.9.2026
Yahoo · 18.9.2026
Zacks · 18.9.2026
MT Newswires · 18.9.2026
MT Newswires · 18.9.2026
SeekingAlpha · 18.9.2026
MT Newswires · 18.9.2026
Simply Wall St. · 18.9.2026
Yahoo · 18.9.2026
Insider Monkey · 18.9.2026
Yahoo · 18.9.2026
GlobeNewswire · 17.9.2026
Yahoo · 17.9.2026
GuruFocus.com · 17.9.2026
Yahoo · 17.9.2026
Insider Monkey · 17.9.2026
Yahoo · 17.9.2026
Business Wire · 17.9.2026
AstraZeneca PLC (AZN) currently has a StockIQ AI score of 66/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
AZN currently scores 66/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, AZN's estimated fair value is $178.03, which is 7.2% above the current price of $166.08. This is one valuation model among several signals in the fair-value category, not a price target.
AZN's technical score is 67/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: SMA 50 recently crossed above SMA 200; Earnings per share (EPS) growth: 45.3%; Net income growth: 45.3%.
Based on the real signals StockIQ computed: Current ratio: 0.94; Calmar: 0.27 (3y annualized return 7.6% / max drawdown 27.9%); Price is below the 200-day average.
Yes — AZN has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 3 purchases and 2 sales out of the last 17 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Sharma Mani | Grant/Award from Employer | 8.9.2026 | 1 | +1 | $162.60 |
| Sharma Mani | Open Market Purchase | 8.8.2026 | 20.233 | +20.233 | $160.57 |
| Sharma Mani | Grant/Award from Employer | 6.8.2026 | 2 | +2 | $163.34 |
| Sharma Mani | Grant/Award from Employer | 6.8.2026 | 19,267 | +2 | $163.34 |
| Sharma Mani | Grant/Award from Employer | 6.7.2026 | 2 | +2 | $190.43 |
| Sharma Mani | Grant/Award from Employer | 6.7.2026 | 19,265 | +2 | $190.43 |
| Sharma Mani | Grant/Award from Employer | 8.6.2026 | 1 | +1 | $179.75 |
| Sharma Mani | Grant/Award from Employer | 8.6.2026 | 19,263 | +1 | $179.75 |
| Sharma Mani | Open Market Sale | 20.5.2026 | 11,893 | -11,893 | $185.78 |
| Sharma Mani | Open Market Sale | 20.5.2026 | 19,262 | -11,893 | $185.78 |
| Sharma Mani | Grant/Award from Employer | 6.5.2026 | 1 | +1 | $186.28 |
| Sharma Mani | Grant/Award from Employer | 7.4.2026 | 1 | +1 | $196.03 |
| ASTRAZENECA PLC | U | 15.3.2021 | 14,650,334 | -14,650,334 | $53.00 |
| ASTRAZENECA PLC | Open Market Purchase | 19.12.2019 | 12,946,900 | +12,946,900 | — |
| ASTRAZENECA PLC | Conversion of Derivative Security | 7.10.2019 | 14,225,324 | -14,225,324 | — |
| ASTRAZENECA PLC | Conversion of Derivative Security | 7.10.2019 | 14,225,324 | +14,225,324 | — |
| ASTRAZENECA PLC | Open Market Purchase | 7.10.2019 | 425,000 | +425,000 | $19.00 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,895,178 shares short as of 2026-08-31 · vs. 1,838,477 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
25.6% of trading volume this week was short selling, vs. 28.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology